TaiGen Biopharmaceuticals Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Philip Huang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	13.3yrs
Promedio de permanencia en la Junta Directiva	11.6yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04

CEO

Philip Huang

5.8yrs

Permanencia

Mr. Kuo-Lung Huang, also known as Philip, serves as General Manager of TiaGen BioPharmaceuticals Co. (Beijing), Ltd. Mr. Huang is Chairman of the Board, President & Chief Executive Officer at TaiGen Biotec...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ming-Chu Hsu	Founder	23.8yrs	NT$15.00k	sin datos
Kuo-Lung Huang	Chairman of the Board	no data	sin datos	sin datos
Richard Lu	Vice President of Finance	8.6yrs	sin datos	sin datos
Mark Kao	Head of the Accounting Department	no data	sin datos	sin datos
Peter Tsao	Vice President Corporate Development	13.3yrs	sin datos	sin datos

13.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 4157 es experimentado (13.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kuo-Lung Huang	Chairman of the Board	5.8yrs	sin datos	sin datos
Ye-Hong Zhang	Independent Director	5.4yrs	sin datos	sin datos
Show-Chung Ho	Director	11.6yrs	NT$123.00k	sin datos
Hong-Jen Chang	Director	14.4yrs	NT$135.00k	sin datos
Kuo-Hsi Wang	Director	15.7yrs	NT$135.00k	sin datos
Shen-Fu Yu	Independent Director	5.4yrs	sin datos	sin datos
Chiung-Feng Ko	Supervisor	12.4yrs	NT$135.00k	sin datos
Shih-Jen Hsiao	Supervisor	11.6yrs	NT$120.00k	sin datos
Ta-Shao Shih	Supervisor	9.4yrs	sin datos	sin datos
Peter Wu	Director	no data	sin datos	sin datos
Weng-Foung Huang	Independent Director	no data	sin datos	sin datos
Chi-Kung Ho	Director	no data	sin datos	sin datos

11.6yrs

Permanencia media

69.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 4157 son experimentados ( 11.6 años antigüedad media).

TaiGen Biopharmaceuticals Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 29, 2024

Less than half of directors are independent

Less than half of directors are independent

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 27, 2021

Recent updates

Third quarter 2024 earnings released: NT$0.10 loss per share (vs NT$0.012 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.09 (vs NT$0.014 in 2Q 2023)

First quarter 2024 earnings released: NT$0.01 loss per share (vs NT$0.07 loss in 1Q 2023)

Full year 2023 earnings released: EPS: NT$0.19 (vs NT$0.33 loss in FY 2022)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: NT$0.01 loss per share (vs NT$0.015 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.015 (vs NT$0.14 loss in 2Q 2022)

Full year 2022 earnings released: NT$0.33 loss per share (vs NT$1.08 profit in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.14 loss per share (vs NT$1.54 profit in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: NT$0.05 loss per share (vs NT$0.061 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.08 (vs NT$0.56 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: NT$0.19 loss per share (vs NT$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.54 (vs NT$0.14 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.10 loss in 1Q 2020)

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Full year 2020 earnings released: NT$0.56 loss per share (vs NT$0.41 loss in FY 2019)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 27, 2021

New 90-day low: NT$17.90

New 90-day low: NT$21.35

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

TaiGen Biotechnology Company, Limited Partners with GPCR Therapeutics, Inc. to Develop Burixafor & Taigexyn(R)

Third quarter 2020 earnings released: NT$0.14 loss per share

First half earnings released

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad